The role of histone deacetylase 3 in breast cancer.
Breast cancer
HDAC
HDAC3
HDAC3 inhibitors
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
17 May 2022
17 May 2022
Historique:
received:
11
12
2021
accepted:
05
02
2022
entrez:
16
5
2022
pubmed:
17
5
2022
medline:
19
5
2022
Statut:
epublish
Résumé
It has been recently revealed that Histone Deacetylase (HDAC) 3, a unique member of the HDACs family, can trigger and progress cancers by alternation in genes expression and proteins activity. Epigenetic modifications by HDACs have been studied well in various cancer cells. Recent studies have focused on the HDAC enzymes as a possible target in cancer therapy. There are significant documents on upregulation of HDAC3 in breast cancer (BC) cells which suggest an oncogenic role for this enzyme. Interestingly, some studies showed that HDAC3 inhibition could be considered as a promising target in breast cancer therapy, and thus far, several inhibitors from different nature have been introduced. In this review, we discussed the function and highlight the existing inhibitors of HDAC3 in BC pathogenesis and therapy.
Identifiants
pubmed: 35578147
doi: 10.1007/s12032-022-01681-4
pii: 10.1007/s12032-022-01681-4
doi:
Substances chimiques
Histone Deacetylase Inhibitors
0
Histone Deacetylases
EC 3.5.1.98
histone deacetylase 3
EC 3.5.1.98
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
84Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
pubmed: 33433946
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.
pubmed: 33538338
Lukasiewicz S, Czeczelewski M, Forma A, Baj J, Sitarz R, Stanislawek A. Breast cancer-epidemiology, risk factors, classification, prognostic markers, and current treatment strategies-an updated review. Cancers (Basel). 2021;13(17):4287.
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181–5.
pubmed: 32056259
Byler S, Goldgar S, Heerboth S, Leary M, Housman G, Moulton K, et al. Genetic and epigenetic aspects of breast cancer progression and therapy. Anticancer Res. 2014;34(3):1071–7.
pubmed: 24596345
Karsli-Ceppioglu S, Dagdemir A, Judes G, Ngollo M, Penault-Llorca F, Pajon A, et al. Epigenetic mechanisms of breast cancer: an update of the current knowledge. Epigenomics. 2014;6(6):651–64.
pubmed: 25531258
Momenimovahed Z, Salehiniya H. Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer (Dove Med Press). 2019;11:151–64.
Biswas S, Rao CM. Epigenetics in cancer: fundamentals and beyond. Pharmacol Ther. 2017;173:118–34.
pubmed: 28188812
Perri F, Longo F, Giuliano M, Sabbatino F, Favia G, Ionna F, et al. Epigenetic control of gene expression: potential implications for cancer treatment. Crit Rev Oncol Hematol. 2017;111:166–72.
pubmed: 28259291
Eckschlager T, Plch J, Stiborova M, Hrabeta J. Histone deacetylase inhibitors as anticancer drugs. Int J Mol Sci. 2017;18(7):1414.
pmcid: 5535906
Baylin SB, Jones PA. Epigenetic determinants of cancer. Cold Spring Harb Perspect Biol. 2016;8(9):a019505.
pubmed: 27194046
pmcid: 5008069
Li G, Tian Y, Zhu WG. The roles of histone deacetylases and their inhibitors in cancer therapy. Front Cell Dev Biol. 2020;8:576946.
pubmed: 33117804
pmcid: 7552186
Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20(3):3898–941.
pubmed: 25738536
pmcid: 4372801
Seto E, Yoshida M. Erasers of histone acetylation: the histone deacetylase enzymes. Cold Spring Harb Perspect Biol. 2014;6(4):a018713.
pubmed: 24691964
pmcid: 3970420
Patra S, Panigrahi DP, Praharaj PP, Bhol CS, Mahapatra KK, Mishra SR, et al. Dysregulation of histone deacetylases in carcinogenesis and tumor progression: a possible link to apoptosis and autophagy. Cell Mol Life Sci. 2019;76(17):3263–82.
pubmed: 30982077
Barneda-Zahonero B, Parra M. Histone deacetylases and cancer. Mol Oncol. 2012;6(6):579–89.
pubmed: 22963873
pmcid: 5528343
Muller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, et al. Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer–overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression. BMC Cancer. 2013;13:215.
pubmed: 23627572
pmcid: 3646665
Salek Farrokhi A, Mohammadlou M, Abdollahi M, Eslami M, Yousefi B. Histone deacetylase modifications by probiotics in colorectal cancer. J Gastrointest Cancer. 2020;51(3):754–64.
pubmed: 31808058
Moufarrij S, Dandapani M, Arthofer E, Gomez S, Srivastava A, Lopez-Acevedo M, et al. Epigenetic therapy for ovarian cancer: promise and progress. Clin Epigenetics. 2019;11(1):7.
pubmed: 30646939
pmcid: 6334391
Tchio Mantho CI, Harbuzariu A, Gonzalez-Perez RR. Histone deacetylases, microRNA and leptin crosstalk in pancreatic cancer. World J Clin Oncol. 2017;8(3):178–89.
pubmed: 28638788
pmcid: 5465008
Darvishi N, Rahimi K, Mansouri K, Fathi F, Menbari MN, Mohammadi G, et al. MiR-646 prevents proliferation and progression of human breast cancer cell lines by suppressing HDAC2 expression. Mol Cell Probes. 2020;53:101649.
pubmed: 32777446
Menbari MN, Rahimi K, Ahmadi A, Elyasi A, Darvishi N, Hosseini V, et al. MiR-216b-5p inhibits cell proliferation in human breast cancer by down-regulating HDAC8 expression. Life Sci. 2019;237:116945.
pubmed: 31605710
Menbari MN, Rahimi K, Ahmadi A, Mohammadi-Yegane S, Elyasi A, Darvishi N, et al. Association of HDAC8 expression with pathological findings in triple negative and non-triple negative breast cancer: implications for diagnosis. Iran Biomed J. 2020;24(5):288–94.
pubmed: 32429642
pmcid: 7392136
Menbari MN, Rahimi K, Ahmadi A, Mohammadi-Yeganeh S, Elyasi A, Darvishi N, et al. miR-483-3p suppresses the proliferation and progression of human triple negative breast cancer cells by targeting the HDAC8>oncogene. J Cell Physiol. 2020;235(3):2631–42.
pubmed: 31508813
Rahmani G, Sameri S, Abbasi N, Abdi M, Najafi R. The clinical significance of histone deacetylase-8 in human breast cancer. Pathol Res Pract. 2021;220:153396.
pubmed: 33691240
Ramaiah MJ, Tangutur AD, Manyam RR. Epigenetic modulation and understanding of HDAC inhibitors in cancer therapy. Life Sci. 2021;277:119504.
pubmed: 33872660
Adhikari N, Amin SA, Trivedi P, Jha T, Ghosh B. HDAC3 is a potential validated target for cancer: an overview on the benzamide-based selective HDAC3 inhibitors through comparative SAR/QSAR/QAAR approaches. Eur J Med Chem. 2018;157:1127–42.
pubmed: 30179749
Zhang L, Chen Y, Jiang Q, Song W, Zhang L. Therapeutic potential of selective histone deacetylase 3 inhibition. Eur J Med Chem. 2019;162:534–42.
pubmed: 30472601
Sarkar R, Banerjee S, Amin SA, Adhikari N, Jha T. Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: a review. Eur J Med Chem. 2020;192:112171.
pubmed: 32163814
Ishii S. The role of histone deacetylase 3 complex in nuclear hormone receptor action. Int J Mol Sci. 2021;22(17):9138.
pubmed: 34502048
pmcid: 8431225
Watson PJ, Fairall L, Santos GM, Schwabe JW. Structure of HDAC3 bound to co-repressor and inositol tetraphosphate. Nature. 2012;481(7381):335–40.
pubmed: 22230954
pmcid: 3272448
Liang N, Jakobsson T, Fan R, Treuter E. The nuclear receptor-co-repressor complex in control of liver metabolism and disease. Front Endocrinol (Lausanne). 2019;10:411.
Kwak SM, Seo J, Hwang JT, Sung GJ, Song JH, Jeong JH, et al. EGFR-c-Src-mediated HDAC3 phosphorylation exacerbates invasion of breast cancer cells. Cells. 2019;8(8):930.
pmcid: 6721651
Kwon Y, Kim Y, Jung HS, Jeoung D. Role of HDAC3-miRNA-CAGE network in anti-cancer drug-resistance. Int J Mol Sci. 2018;20(1):51.
pmcid: 6337380
Seo J, Guk G, Park SH, Jeong MH, Jeong JH, Yoon HG, et al. Tyrosine phosphorylation of HDAC3 by Src kinase mediates proliferation of HER2-positive breast cancer cells. J Cell Physiol. 2019;234(5):6428–36.
pubmed: 30317579
Zhang F, Qi L, Feng Q, Zhang B, Li X, Liu C, et al. HIPK2 phosphorylates HDAC3 for NF-kappaB acetylation to ameliorate colitis-associated colorectal carcinoma and sepsis. Proc Natl Acad Sci U S A. 2021;118(28):e2021798118.
pubmed: 34244427
pmcid: 8285910
Glozak MA, Seto E. Histone deacetylases and cancer. Oncogene. 2007;26(37):5420–32.
pubmed: 17694083
Lkhagva B, Kao YH, Lee TI, Lee TW, Cheng WL, Chen YJ. Activation of class I histone deacetylases contributes to mitochondrial dysfunction in cardiomyocytes with altered complex activities. Epigenetics. 2018;13(4):376–85.
pubmed: 29613828
pmcid: 6140820
Xu Z, Tong Q, Zhang Z, Wang S, Zheng Y, Liu Q, et al. Inhibition of HDAC3 prevents diabetic cardiomyopathy in OVE26 mice via epigenetic regulation of DUSP5-ERK1/2 pathway. Clin Sci (Lond). 2017;131(15):1841–57.
He X, Zhang L, Queme LF, Liu X, Lu A, Waclaw RR, et al. A histone deacetylase 3-dependent pathway delimits peripheral myelin growth and functional regeneration. Nat Med. 2018;24(3):338–51.
pubmed: 29431744
pmcid: 5908710
Siebzehnrubl FA, Raber KA, Urbach YK, Schulze-Krebs A, Canneva F, Moceri S, et al. Early postnatal behavioral, cellular, and molecular changes in models of Huntington disease are reversible by HDAC inhibition. Proc Natl Acad Sci U S A. 2018;115(37):E8765–74.
pubmed: 30150378
pmcid: 6140493
Amin SA, Adhikari N, Kotagiri S, Jha T, Ghosh B. Histone deacetylase 3 inhibitors in learning and memory processes with special emphasis on benzamides. Eur J Med Chem. 2019;166:369–80.
pubmed: 30735902
Zhao B, Yuan Q, Hou JB, Xia ZY, Zhan LY, Li M, et al. Inhibition of HDAC3 ameliorates cerebral ischemia reperfusion injury in diabetic mice in vivo and in vitro. J Diabetes Res. 2019;2019:8520856.
pubmed: 30906786
pmcid: 6393870
Tong L, Liang H, Zhuang H, Liu C, Zhang Z. The relationship between HDAC3 and malignant tumors: a mini review. Crit Rev Eukaryot Gene Expr. 2020;30(3):279–84.
pubmed: 32749115
Adhikari N, Jha T, Ghosh B. Dissecting histone deacetylase 3 in multiple disease conditions: selective inhibition as a promising therapeutic strategy. J Med Chem. 2021;64(13):8827–69.
pubmed: 34161101
Ma L, Qi L, Li S, Yin Q, Liu J, Wang J, et al. Aberrant HDAC3 expression correlates with brain metastasis in breast cancer patients. Thorac Cancer. 2020;11(9):2493–505.
pubmed: 32686908
pmcid: 7471029
Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–76.
pubmed: 19103471
Xu G, Zhu H, Zhang M, Xu J. Histone deacetylase 3 is associated with gastric cancer cell growth via the miR-454-mediated targeting of CHD5. Int J Mol Med. 2018;41(1):155–63.
pubmed: 29115379
Yang Z, Jiang X, Zhang Z, Zhao Z, Xing W, Liu Y, et al. HDAC3-dependent transcriptional repression of FOXA2 regulates FTO/m6A/MYC signaling to contribute to the development of gastric cancer. Cancer Gene Ther. 2021;28(1–2):141–55.
pubmed: 32655129
Zhang L, Liu F, Meng Z, Luo Q, Pan D, Qian Y. Inhibited HDAC3 promotes microRNA-376c-3p to suppress malignant phenotypes of gastric cancer cells by reducing WNT2b. Genomics. 2021;113(6):3512–22.
pubmed: 34284078
Wu SM, Jan YJ, Tsai SC, Pan HC, Shen CC, Yang CN, et al. Targeting histone deacetylase-3 blocked epithelial-mesenchymal plasticity and metastatic dissemination in gastric cancer. Cell Biol Toxicol. 2022. https://doi.org/10.1007/s10565-021-09673-2 .
doi: 10.1007/s10565-021-09673-2
pubmed: 35648318
pmcid: 8882720
Li H, Li H, Waresijiang Y, Chen Y, Li Y, Yu L, et al. Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma. Exp Ther Med. 2020;20(1):315–24.
pubmed: 32536999
pmcid: 7282189
Lucio-Eterovic AK, Cortez MA, Valera ET, Motta FJ, Queiroz RG, Machado HR, et al. Differential expression of 12 histone deacetylase (HDAC) genes in astrocytomas and normal brain tissue: class II and IV are hypoexpressed in glioblastomas. BMC Cancer. 2008;8:243.
pubmed: 18713462
pmcid: 2536671
Nemati M, Ajami N, Estiar MA, Rezapour S, Gavgani RR, Hashemzadeh S, et al. Deregulated expression of HDAC3 in colorectal cancer and its clinical significance. Adv Clin Exp Med. 2018;27(3):305–11.
pubmed: 29558042
Ren H, Tang L. HDAC3-mediated lncRNA-LOC101928316 contributes to cisplatin resistance in gastric cancer via activating the PI3K-Akt-mTOR pathway. Neoplasma. 2021;68(5):1043–51.
pubmed: 34427099
Zhang L, Hong Z, Zhang RR, Sun XZ, Yuan YF, Hu J, et al. Bakkenolide A inhibits leukemia by regulation of HDAC3 and PI3K/Akt-related signaling pathways. Biomed Pharmacother. 2016;83:958–66.
pubmed: 27522258
Lou T, Zhuang H, Liu C, Zhang Z. HDAC3 positively regulates HE4 expression to promote ovarian carcinoma progression. Arch Biochem Biophys. 2019;675:108044.
pubmed: 31302139
Quiroz-Reyes AG, Delgado-Gonzalez P, Islas JF, Gallegos JLD, Martinez Garza JH, Garza-Trevino EN. Behind the adaptive and resistance mechanisms of cancer stem cells to TRAIL. Pharmaceutics. 2021;13(7):1062.
pubmed: 34371753
pmcid: 8309156
Zhang B, Liu B, Chen D, Setroikromo R, Haisma HJ, Quax WJ. Histone deacetylase inhibitors sensitize TRAIL-induced apoptosis in colon cancer cells. Cancers (Basel). 2019;11(5):645.
Lombard DB, Cierpicki T, Grembecka J. Combined MAPK pathway and HDAC inhibition breaks melanoma. Cancer Discov. 2019;9(4):469–71.
pubmed: 30936219
pmcid: 6446927
Trivedi P, Adhikari N, Amin SA, Jha T, Ghosh B. Design, synthesis and biological screening of 2-aminobenzamides as selective HDAC3 inhibitors with promising anticancer effects. Eur J Pharm Sci. 2018;124:165–81.
pubmed: 30171982
Zhou L, Xu X, Liu H, Hu X, Zhang W, Ye M, et al. Prognosis analysis of histone deacetylases mRNA expression in ovarian cancer patients. J Cancer. 2018;9(23):4547–55.
pubmed: 30519361
pmcid: 6277648
Hu G, He N, Cai C, Cai F, Fan P, Zheng Z, et al. HDAC3 modulates cancer immunity via increasing PD-L1 expression in pancreatic cancer. Pancreatology. 2019;19(2):383–9.
pubmed: 30670333
Shouksmith AE, Shah F, Grimard ML, Gawel JM, Raouf YS, Geletu M, et al. Identification and characterization of AES-135, a hydroxamic acid-based HDAC inhibitor that prolongs survival in an orthotopic mouse model of pancreatic cancer. J Med Chem. 2019;62(5):2651–65.
pubmed: 30776234
pmcid: 7190078
Cui Z, Xie M, Wu Z, Shi Y. Relationship between histone deacetylase 3 (HDAC3) and breast cancer. Med Sci Monit. 2018;24:2456–64.
pubmed: 29680858
pmcid: 5935015
Mirsadeghi L, Haji Hosseini R, Banaei-Moghaddam AM, Kavousi K. EARN: an ensemble machine learning algorithm to predict driver genes in metastatic breast cancer. BMC Med Genomics. 2021;14(1):122.
pubmed: 33962648
pmcid: 8105935
Su W, Zeng L, Chen W. Moscatilin suppresses the breast cancer both in vitro and in vivo by inhibiting HDAC3. Dose Response. 2021;19(1):15593258211001252.
pubmed: 33795998
pmcid: 7968028
Yang M, Dang X, Tan Y, Wang M, Li X, Li G. I-7ab inhibited the growth of TNBC cells via targeting HDAC3 and promoting the acetylation of p53. Biomed Pharmacother. 2018;99:220–6.
pubmed: 29334665
Chen SY, Teng SC, Cheng TH, Wu KJ. miR-1236 regulates hypoxia-induced epithelial-mesenchymal transition and cell migration/invasion through repressing SENP1 and HDAC3. Cancer Lett. 2016;378(1):59–67.
pubmed: 27177472
Ververis K, Karagiannis TC. An atlas of histone deacetylase expression in breast cancer: fluorescence methodology for comparative semi-quantitative analysis. Am J Transl Res. 2012;4(1):24–43.
pubmed: 22347520
pmcid: 3276375
Bayat S, Mansoori Derakhshan S, Mansoori Derakhshan N, Shekari Khaniani M, Alivand MR. Downregulation of HDAC2 and HDAC3 via oleuropein as a potent prevention and therapeutic agent in MCF-7 breast cancer cells. J Cell Biochem. 2019;120(6):9172–80.
pubmed: 30618185
Lee JY, Kuo CW, Tsai SL, Cheng SM, Chen SH, Chan HH, et al. Inhibition of HDAC3- and HDAC6-promoted survivin expression plays an important role in SAHA-induced autophagy and viability reduction in breast cancer cells. Front Pharmacol. 2016;7:81.
pubmed: 27065869
pmcid: 4814469
Hanigan TW, Aboukhatwa SM, Taha TY, Frasor J, Petukhov PA. Divergent JNK phosphorylation of HDAC3 in triple-negative breast cancer cells determines HDAC inhibitor binding and selectivity. Cell Chem Biol. 2017;24(11):1356-67 e8.
pubmed: 28943357
pmcid: 5693607
Qiao W, Liu H, Liu R, Liu Q, Zhang T, Guo W, et al. Prognostic and clinical significance of histone deacetylase 1 expression in breast cancer: a meta-analysis. Clin Chim Acta. 2018;483:209–15.
pubmed: 29738697
Wei H, Ma W, Lu X, Liu H, Lin K, Wang Y, et al. KDELR2 promotes breast cancer proliferation via HDAC3-mediated cell cycle progression. Cancer Commun (London). 2021. https://doi.org/10.1002/cac2.12180 .
doi: 10.1002/cac2.12180
Krusche CA, Wulfing P, Kersting C, Vloet A, Bocker W, Kiesel L, et al. Histone deacetylase-1 and -3 protein expression in human breast cancer: a tissue microarray analysis. Breast Cancer Res Treat. 2005;90(1):15–23.
pubmed: 15770522
Seo J, Min SK, Park HR, Kim DH, Kwon MJ, Kim LS, et al. Expression of histone deacetylases HDAC1, HDAC2, HDAC3, and HDAC6 in invasive ductal carcinomas of the breast. J Breast Cancer. 2014;17(4):323–31.
pubmed: 25548579
pmcid: 4278050
Park SH, Kim H, Kwak S, Jeong JH, Lee J, Hwang JT, et al. HDAC3-ERalpha selectively regulates TNF-alpha-induced apoptotic cell death in MCF-7 human breast cancer cells via the p53 signaling pathway. Cells. 2020;9(5):1280.
pmcid: 7290399
Oie S, Matsuzaki K, Yokoyama W, Murayama A, Yanagisawa J. HDAC3 regulates stability of estrogen receptor alpha mRNA. Biochem Biophys Res Commun. 2013;432(2):236–41.
pubmed: 23402757
Yu S, Gong X, Ma Z, Zhang M, Huang L, Zhang J, et al. Endocrine resistant breast cancer cells with loss of ERalpha expression retain proliferative ability by reducing caspase7-mediated HDAC3 cleavage. Cell Oncol (Dordr). 2020;43(1):65–80.
Zhao Y, He J, Yang L, Luo Q, Liu Z. Histone deacetylase-3 modification of MicroRNA-31 promotes cell proliferation and aerobic glycolysis in breast cancer and is predictive of poor prognosis. J Breast Cancer. 2018;21(2):112–23.
pubmed: 29963106
pmcid: 6015978
Feng W, Lu Z, Luo RZ, Zhang X, Seto E, Liao WS, et al. Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. Int J Cancer. 2007;120(8):1664–8.
pubmed: 17230502
Darvin P, Sasidharan Nair V, Elkord E. PD-L1 expression in human breast cancer stem cells is epigenetically regulated through posttranslational histone modifications. J Oncol. 2019;2019:3958908.
pubmed: 30915120
pmcid: 6409026
Fermento ME, Gandini NA, Salomon DG, Ferronato MJ, Vitale CA, Arevalo J, et al. Inhibition of p300 suppresses growth of breast cancer. Role of p300 subcellular localization. Exp Mol Pathol. 2014;97(3):411–24.
pubmed: 25240203
Lucas J, Hsieh TC, Halicka HD, Darzynkiewicz Z, Wu JM. Upregulation of PDL1 expression by resveratrol and piceatannol in breast and colorectal cancer cells occurs via HDAC3/p300mediated NFkappaB signaling. Int J Oncol. 2018;53(4):1469–80.
pubmed: 30066852
pmcid: 6086626
Liu J, He D, Cheng L, Huang C, Zhang Y, Rao X, et al. p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer. Oncogene. 2020;39(19):3939–51.
pubmed: 32203167
pmcid: 7210073
Hsieh HY, Chuang HC, Shen FH, Detroja K, Hsin LW, Chen CS. Targeting breast cancer stem cells by novel HDAC3-selective inhibitors. Eur J Med Chem. 2017;140:42–51.
pubmed: 28923385
Routholla G, Pulya S, Patel T, Abdul Amin S, Adhikari N, Biswas S, et al. Synthesis, biological evaluation, and molecular docking analysis of novel linker-less benzamide based potent and selective HDAC3 inhibitors. Bioorgan Chem. 2021;114:105050.
Putri AD, Chen PS, Su YL, Lin JP, Liou JP, Hsieh CM. Optimization and development of selective histone deacetylase inhibitor (MPT0B291)-loaded albumin nanoparticles for anticancer therapy. Pharmaceutics. 2021;13(10):1728.
pubmed: 34684020
pmcid: 8541575
Luo G, Lin X, Ren S, Wu S, Wang X, Ma L, et al. Development of novel tetrahydroisoquinoline-hydroxamate conjugates as potent dual SERDs/HDAC inhibitors for the treatment of breast cancer. Eur J Med Chem. 2021;226:113870.
pubmed: 34610548
Subramanian S, Bates SE, Wright JJ, Espinoza-Delgado I, Piekarz RL. Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals (Basel). 2010;3(9):2751–67.
Benedetti R, Conte M, Altucci L. Targeting histone deacetylases in diseases: where are we? Antioxid Redox Signal. 2015;23(1):99–126.
pubmed: 24382114
pmcid: 4492558